Across TCGA pan-cancer cohorts, GCGR Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GCGR data layer compared with 26 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher GCGR Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GCGR expression acts as an unfavorable survival marker.
SARC and UCEC are the cancer types where GCGR Mutation most reproducibly stratifies survival.